Command Palette

Search for a command to run...

Clinical Trials · NCT04839237

The Effect and the Pharmacogenomics Study of Liraglutide in Obese Patients

WithdrawnPhase 2Liraglutide (Prohibited)
Phase
Phase 2
Recruitment status
Withdrawn
Sponsor
Xiangya Hospital of Central South University
Enrollment
0
Start date
Dec 2017
Locations
1 site, China
Primary endpoint
Weight Change at 3 months
View Liraglutide compound reference